June 2016
Authors:
Jennifer M. Spangle, Koen M. Dreijerink, Anna C. Groner, Hailing Cheng, Carolynn E. Ohlson, Jaime Reyes, Charles Y. Lin, James Bradner, Jean J. Zhao, Thomas M. Roberts, and Myles Brown
Info:
In this breast cancer research study, scientists evaluate the PI3K/AKT signaling pathway on the epigentic methylation of the H3 histone in cells which is implicated in cell growth for late stage cancers. They suggest that the H3K4 gene may be useful epigenetic markers for PI3K/AKT inhibitors in clinical development. Pippin Prep was used for the ChIP-seq size selection.
This study was a collaboration with the Dana Farber Cancer Institute, Harvard Medical School, and The Second Hospital of Dalian Medical University, China.
Citation:
Cell Reports 15, 2692–2704
doi.org/10.1016/j.celrep.2016.05.046